Domperidone QT — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Additive QT prolongation and arrhythmia risk
This scenario assesses Domperidone QT in a UK pharmacy practice context. Domperidone can prolong QT interval, especially with cardiac disease and other QT-prolonging medicines. The best answer is Additive QT prolongation and arrhythmia risk because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.
Reference: BNF; MHRA Drug Safety Update